| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
LENZ Therapeutics, Inc.$5.59
-0.2 (-3.45%)
D 37Pipeline Score Overvalued Biotech · Commercial
Market Cap
236.73 M
EPS
-3.59
P/E Ratio
-
Value Trade
3.59 M
SEC Financials
Q1 2026Dilution Risk
Revenue
1.90 M
R&D Expenses
-
Operating CF
-33.58 M
Total Assets
272.54 M
Total Liabilities
26.04 M
Equity
246.49 M
D/E Ratio
12,345
5.15 %
Week
-24.58 %
1 Month
-36.71 %
3 Month
-72.73 %
6 Month
-95.12 %
5 Year
-95.12 %
All Time
Cash Data
Cash Position
258.38 M
Monthly Burn
11.19 M
Runway
21.1 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
1.20 M
52 Week Range
6.61 - 50.40
% held by Insiders
12.74 %
% held by Institutions
100.31 %
Enterprise Value
-20.99 M
Total Shares
31.33 M
Short %
57.12 %
Float Shares
18.26 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for LENZ Therapeutics, Inc.
197Total events
1Upcoming
62Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 1
Event history 196
Jul 6, 2026
▲Product LaunchVIZZApprovedPost-Market
Launch of telehealth prescribing option for VIZZ
presbyopiasource ↗
Jun 24, 2026
▲Partnership / LicenseVIZZApprovedCorporate
Exclusive license and commercialization agreement with Arrotex for VIZZ in Australia and New Zealand
presbyopiasource ↗
Jun 9, 2026
Jun 7, 2026
▲Partnership / LicenseVIZZApprovedCorporate
Everest Medicines acquires rights to develop and commercialize VIZZ (LNZ100) in Greater China
presbyopiasource ↗
May 11, 2026
◆Quarterly UpdateCorporate
First Quarter 2026 Financial Results and Recent Corporate Highlights Webcast
Apr 20, 2026
Q2 2026
●Timing GuidancePresentation
DTC campaign expansion into network television advertising in select markets in early Q2 2026
Apr 2026
▲Quarterly UpdateCorporate
Pilot expansion of DTC campaign into network and cable television advertising
Drug Pipeline Intelligence
D37
Pipeline Score $142M
Pipeline ValueOvervalued
Valuation Signal6
Drugs Scored0.6x
rNPV / MCap Top 51%
Micro Cap (rank 448 of 912)
Percentile RankLENZ Therapeutics, Inc. faces pipeline headwinds (37/100), with $1.2B risk-adjusted pipeline value, led by Drug: GB-102 in Neovascular Age-Related Macular Degeneration (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug: GB-102 Small molecule | Neovascular Age-Related Macular Degeneration | Phase 2 | NCT03953079 | 15% | $476M | COMPLETED | 56 | - | - | Jun 3, 2021 | - | Jan 19, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
LNZ100 | presbyopia | Phase 3 | 2024-10-27 | 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment; 69% of participants showing improvement within 30 minutes; 91% of participants indicated they noticed an improvement in their near vision; 84% and 69% achieved two-lines and three-lines or greater improvement at 30 minutes respectively; 88% and 74% achieved two-lines and three-lines or greater improvement at 3 hours respectively; 61% and 30% achieved two-lines and three-lines or greater improvement at 10 hours respectively Read More | CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement a Read More | |
LNZ100 | presbyopia | Phase 3 | 2024-10-27 | 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment; 69% of participants showing improvement within 30 minutes; 91% of participants indicated they noticed an improvement in their near vision; 84% and 69% achieved two-lines and three-lines or greater improvement at 30 minutes respectively; 88% and 74% achieved two-lines and three-lines or greater improvement at 3 hours respectively; 61% and 30% achieved two-lines and three-lines or greater improvement at 10 hours respectively Read More | CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement a Read More | |
LNZ100 | presbyopia | Phase 3 | 2024-10-27 | 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment; 69% of participants showing improvement within 30 minutes; 91% of participants indicated they noticed an improvement in their near vision; 84% and 69% achieved two-lines and three-lines or greater improvement at 30 minutes respectively; 88% and 74% achieved two-lines and three-lines or greater improvement at 3 hours respectively; 61% and 30% achieved two-lines and three-lines or greater improvement at 10 hours respectively Read More | CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement a Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LENZ
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LENZ Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LENZLENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
LENZ Therapeutics has launched a telehealth prescribing option for its eye drop VIZZ, aimed at improving access for patients with presbyopia. This new platform allows for online evaluations by licensed eye care providers and includes home delivery of prescriptions. The initiative is supported by a national advertising campaign featuring Sarah Jessica Parker to increase awareness and adoption of VIZZ.
Read more →LENZLENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand
LENZ Therapeutics has entered an exclusive license and commercialization agreement with Arrotex Pharmaceuticals for VIZZ, an FDA-approved treatment for presbyopia, in Australia and New Zealand. This partnership marks LENZ's fifth international collaboration for VIZZ, aiming to enhance patient access to this innovative therapy. The agreement includes an upfront payment and profit-sharing from sales.
Read more →LENZLENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ (LNZ100) in Greater China
LENZ Therapeutics has partnered with Everest Medicines, which acquired the rights to develop and commercialize VIZZ (LNZ100) in Greater China. This ophthalmic solution is designed to treat presbyopia and will be marketed following its New Drug Application, submitted in September 2025, with approval expected in early 2027. LENZ stands to gain up to $85 million in milestone payments along with royalties on sales. Everest Medicines aims to address significant unmet needs in the presbyopia treatment market with this acquisition.
Read more →LENZLENZ Therapeutics to Participate in Upcoming Investor Conferences
LENZ Therapeutics announced its participation in several upcoming investor conferences, including the William Blair Annual Growth Stock Conference, the Jefferies Global Healthcare Conference, and the Goldman Sachs Global Healthcare Conference. The company is focused on the commercialization of VIZZ, the first FDA-approved aceclidine-based eye drop for presbyopia. This product targets a large market, with millions affected by the condition.
Read more →LENZLENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
LENZ Therapeutics reported a total revenue of $1.9 million for the first quarter of 2026, driven largely by sales of its product VIZZ. The company has expanded its sales force and launched a direct-to-consumer advertising campaign featuring Sarah Jessica Parker, which has led to increased consumer engagement. Despite strong product uptake, LENZ reported a net loss of $41.5 million, reflecting significant expenses related to marketing and the expansion of operations. The management aims to enhance ECP integration of VIZZ and build a robust consumer market for the treatment of presbyopia.
Read more →LENZLENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference
LENZ Therapeutics will report its first quarter 2026 financial results on May 11, 2026, during a webcast. The company is known for its FDA-approved aceclidine ophthalmic solution, VIZZ, which treats presbyopia. Additionally, management will participate in one-on-one meetings at the Bank of America Global Healthcare Conference in Las Vegas from May 13-14, 2026.
Read more →LENZ▼ -8.4%on this news
LENZ Therapeutics, Inc. Investigated by the Portnoy Law Firm
LENZ Therapeutics, Inc. is being investigated by the Portnoy Law Firm for possible securities fraud after a significant drop in stock price. On December 12, 2025, the company's stock plummeted by 25.96% to $18.14 per share, largely due to adverse safety data regarding its VIZZ eye drop. Reports of a retinal tear linked to the product raised safety concerns, triggering a loss of investor confidence and highlighting the risks associated with the product. The law firm is seeking investors who wish to pursue claims related to these developments.
Read more →LENZLENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ for the Treatment of Presbyopia in the United Kingdom
LENZ Therapeutics has submitted a Marketing Authorization Application (MAA) for VIZZ to the UK’s MHRA, following its FDA approval in July 2025. VIZZ is the first aceclidine-based eye drop for treating presbyopia, aimed at improving near vision for adults. The submission marks the company's commitment to international expansion, backed by data from three successful Phase 3 trials in the U.S. These trials demonstrated rapid vision improvement and highlighted VIZZ's tolerability.
Read more →LENZ▼ -17.9%on this news
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
LENZ Therapeutics reported strong financial results for Q4 2025, with $1.6 million in revenues from its newly launched product VIZZ for presbyopia. The company has seen significant prescriber adoption and consumer engagement through marketing efforts. Despite a notable net loss, management remains optimistic about VIZZ's market potential and plans to expand its sales force and marketing strategies.
Read more →LENZ▲ +6.5%on this news
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
LENZ Therapeutics will host a webcast on March 24, 2026, to report its fourth quarter and full year 2025 financial results. The company is known for VIZZ, the first FDA-approved aceclidine-based eye drop for presbyopia. This event reflects the company's commitment to transparency and ongoing corporate updates.
Read more →LENZLENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ for the Treatment of Presbyopia
LENZ Therapeutics has submitted a Marketing Authorization Application to the European Medicines Agency for VIZZ, the first aceclidine-based eye drop for treating presbyopia. This application follows previous submissions, underscoring the company's strategy to expand VIZZ's global reach. Phase 3 studies have shown positive results in improving near vision with excellent safety tolerability. If approved, VIZZ could significantly impact millions of Europeans suffering from age-related vision issues.
Read more →LENZLENZ Therapeutics to Present at Upcoming Investor Conferences
LENZ Therapeutics will present at two upcoming investor conferences in March 2026. The TD Cowen 46th Annual Health Care Conference will take place on March 2 in Boston, followed by the Leerink Partners 2026 Global Healthcare Conference on March 10 in Miami. The company focuses on its FDA-approved eye drop, VIZZ, for treating presbyopia.
Read more →LENZ▲ +12%on this news
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
LENZ Therapeutics has launched the 'Make it VIZZable' campaign featuring Sarah Jessica Parker, promoting VIZZ, a once-daily eye drop aimed at treating age-related blurry near vision. The campaign showcases Parker's personal experiences with presbyopia and emphasizes the convenience of using VIZZ over traditional reading glasses. Clinical trials indicate that VIZZ can significantly improve near vision for up to 10 hours.
Read more →LENZLENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates Launched VIZZ TM (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia,
LENZ Therapeutics has reported preliminary unaudited financial results for Q4 2025, highlighting a successful launch of its eye drop product, VIZZ, for presbyopia. The company achieved approximately $1.6 million in net revenue and filled over 20,000 prescriptions within the first quarter of the product's launch. Additionally, the company has entered a partnership for VIZZ's commercialization in the Middle East, signaling its intention to expand internationally. Overall, the report reflects strong early market acceptance and growth potential for VIZZ.
Read more →LENZLENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
LENZ Therapeutics has partnered with Lunatus for the exclusive commercialization of VIZZ, an FDA-approved eye drop for presbyopia, in the Middle East. This partnership allows Lunatus to manage distribution across several countries, including the UAE and Saudi Arabia. LENZ will benefit from milestone payments and revenue sharing as they expand their market presence.
Read more →LENZLENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
LENZ Therapeutics has announced the submission of a New Drug Application for its product VIZZ™ (aceclidine ophthalmic solution) to the Ministry of Food and Drug Safety in South Korea. The application is supported by successful Phase 3 clinical trial results, showing significant improvements in near vision for presbyopic patients. Under a licensing agreement with Lotus Pharmaceutical, LENZ stands to gain substantial financial benefits from regulatory and commercial milestones. However, the product may cause mild side effects, which are typical for such treatments.
Read more →LENZ▼ -23.5%on this news
LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
LENZ Therapeutics announced the FDA approval of VIZZ, the first aceclidine-based eye drop for presbyopia. The product launched commercially in October 2025, with over 2,500 eye care professionals prescribing it. The company reported a net loss of $16.7 million for Q3 2025, while also partnering with Sarah Jessica Parker for a marketing campaign set to launch in Q1 2026.
Read more →LENZLENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025
LENZ Therapeutics has announced plans to host a webcast on November 5, 2025, to report its third quarter financial results and recent corporate developments. The company focuses on the commercialization of VIZZ™, the only FDA-approved aceclidine-based eye drop aimed at treating presbyopia. Presbyopia is a widespread condition affecting billions globally, highlighting the potential market for LENZ's product. The webcast will offer participants insights into the company's financial performance and future directions.
Read more →LENZLENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
LENZ Therapeutics has announced the commercial availability of VIZZ, the first FDA-approved aceclidine-based eye drop for presbyopia. Product shipments to consumers will begin in October 2025, with broader availability expected by mid-Q4 2025. VIZZ offers up to 10 hours of improved near vision, benefiting millions of adults affected by this condition.
Read more →LENZLENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
LENZ Therapeutics will present at several upcoming investor and medical conferences, showcasing its FDA-approved eye drop, VIZZ, for treating presbyopia. The conferences include notable events like Citi's BioPharma Back to School Conference and the H.C. Wainwright Global Investment Conference. VIZZ aims to improve near vision for adults suffering from age-related vision loss.
Read more →LENZLENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
LENZ Therapeutics has received FDA approval for VIZZ, the first aceclidine-based eye drop for presbyopia. This once-daily treatment improves near vision for up to 10 hours and is expected to be available by mid-Q4 2025. The approval is based on successful Phase 3 trials demonstrating significant efficacy and safety.
Read more →LENZLENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
LENZ Therapeutics has reported its financial results for Q2 2025 and highlighted its progress ahead of the anticipated FDA decision on LNZ100, aimed at treating presbyopia. The company has a PDUFA target action date set for August 8, 2025, and has built a sales team prepared for immediate activities upon approval. LENZ has secured multiple international licensing deals, bringing significant upfront and milestone payments, further positioning the product for a global market launch. Financially, the company holds a strong cash position with over $209 million, supporting operations through the anticipated commercialization phase.
Read more →LENZLENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia
LENZ Therapeutics has announced the submission of a New Drug Application for LNZ100 to the NMPA in China, following positive results from a Phase 3 clinical trial. This submission represents a key milestone in their partnership with CORXEL Pharmaceuticals. If approved, LNZ100 could become a global treatment option for presbyopia, a condition affecting millions worldwide.
Read more →LENZLENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
LENZ Therapeutics has entered into an exclusive licensing and commercialization agreement with Laboratoires Th a for LNZ100, an aceclidine-based eye drop aimed at treating presbyopia in Canada. The deal could yield over $70 million in milestone payments for LENZ. This partnership marks LENZ's third international collaboration for LNZ100, which is awaiting FDA approval with a target action date of August 8, 2025.
Read more →LENZLENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
LENZ Therapeutics has entered an exclusive licensing agreement with Lotus Pharmaceutical to commercialize LNZ100, an aceclidine-based eye drop for presbyopia, in South Korea and Southeast Asia. The agreement could yield up to $125 million in payments for LENZ, along with royalties on future sales. Lotus aims to leverage its commercial capabilities to provide access to this innovative treatment.
Read more →LENZLENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
LENZ Therapeutics reported its first quarter 2025 financial results, emphasizing progress toward the August 8, 2025 PDUFA action date for its New Drug Application (NDA) for LNZ100. The company reported a cash position of $194.1 million, expected to fund operations through the anticipated launch of LNZ100, aimed at treating presbyopia. Recent communications with the FDA indicated a smooth review process with no significant issues. Additionally, pre-launch activities are proceeding on schedule, highlighting the company’s readiness for commercialization.
Read more →LENZ▼ -11%on this newsshared move
LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference
LENZ Therapeutics, Inc. will participate in the BofA Securities 2025 Health Care Conference from May 13-15, 2025, in Las Vegas, NV. The company focuses on developing and commercializing LNZ100, an aceclidine-based eye drop aimed at improving near vision for those with presbyopia. The FDA has set a PDUFA target action date of August 8, 2025, for LNZ100, signaling its importance in addressing a condition affecting millions. This event will include both a fireside chat and one-on-one meetings with company management.
Read more →LENZ▲ +7.1%on this news
LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025
LENZ Therapeutics, a pre-commercial biopharmaceutical company, will report its first quarter 2025 financial results and corporate highlights on May 7th, 2025. The company is advancing its aceclidine-based eye drop, LNZ100, aimed at improving near vision for those with presbyopia. A target action date of August 8, 2025 has been set by the FDA for this product candidate, highlighting its significance in development. A webcast of the report will be available for participants to join.
Read more →LENZLENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
LENZ Therapeutics reported its financial results for the fourth quarter and full year 2024, highlighting significant progress with its treatment LNZ100 for presbyopia. The company anticipates a PDUFA action date of August 8, 2025, for its New Drug Application with the FDA. Financially, LENZ holds $209.1 million, which is expected to support operations through commercialization. The recent Phase 3 CLARITY study yielded positive data, confirming the efficacy of LNZ100, paving the way for potential launch activities to begin soon after FDA approval.
Read more →LENZLENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025
LENZ Therapeutics, a pre-commercial biopharmaceutical company, has announced plans to report its fourth quarter and full year 2024 financial results and corporate highlights on March 19, 2025. The company is focused on its aceclidine-based eye drop, LNZ100, aimed at improving near vision for patients with presbyopia. This condition significantly impacts a large portion of the global population. The FDA has set a target action date for LNZ100 on August 8, 2025, highlighting the importance of this development for future commercialization.
Read more →LENZLENZ Therapeutics to Host Commercial Day on April 15, 2025
LENZ Therapeutics, a pre-commercial biopharmaceutical company, has announced it will host a Commercial Day on April 15, 2025. The event will highlight the company's commercialization strategy and progress towards the FDA's approval of its product candidate, LNZ100, aimed at treating presbyopia. The presentations will include management insights, supply chain readiness, and expert perspectives, underscoring the company's commitment to bringing its innovative eye drop to market.
Read more →LENZ▲ +12.5%on this news· ran to +25% by day 3
LENZ Therapeutics Reports Third Quarter 2024 Financial Results
LENZ Therapeutics reported its third-quarter 2024 financial results, announcing that their New Drug Application for LNZ100 was accepted by the FDA for the treatment of presbyopia. Positive topline data from a Phase 3 study in China has bolstered the drug's potential as a leading therapy in a market with a significant patient population. The company's cash position stands at $217.2 million, expected to fund operations into post-launch positive cash flow. However, they continue to report net losses, reflecting ongoing financial challenges as they prepare for a commercial launch in 2025.
Read more →LENZLENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024
LENZ Therapeutics, a pre-commercial biopharmaceutical company, will report its third quarter 2024 financial results and provide a business update on November 6, 2024. The company is developing LNZ100, an aceclidine-based eye drop aimed at improving near vision in individuals with presbyopia. The FDA has set a Prescription Drug User Fee Act target action date for LNZ100 for August 8, 2025. This upcoming event indicates LENZ's commitment to transparency and updating stakeholders on its progress.
Read more →LENZ▲ +5.5%on this newsshared move
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement a
CORXEL and LENZ Therapeutics announced successful topline results from a Phase 3 trial in China for LNZ100, an aceclidine-based eye drop aimed at treating presbyopia. The trial demonstrated that 74% of participants achieved a significant improvement in their vision. Rapid onset efficacy was noted, with 69% of participants showing improvement within 30 minutes. The study findings suggest a favorable safety profile, with no serious adverse events reported, indicating a promising new option for managing presbyopia.
Read more →LENZLENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
LENZ Therapeutics announced that the FDA has accepted its New Drug Application for LNZ100, an aceclidine-based eye drop designed to improve near vision in individuals with presbyopia. This condition affects approximately 1.8 billion people globally, with 128 million in the United States. The FDA has set a target action date of August 8, 2025, for potential approval. The acceptance marks an important milestone for LENZ Therapeutics as it prepares for commercialization, led by a strong team focused on establishing LNZ100 as a standard treatment.
Read more →LENZLENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
LENZ Therapeutics is set to showcase its aceclidine-based eye drop, LNZ100, at upcoming ophthalmology and optometry conferences. Key presentations will include Phase 3 study data and analyses related to pupil size effects on vision. The company aims to provide treatment for presbyopia, a condition that affects millions globally, and has recently submitted a New Drug Application to the FDA. These presentations will enhance the visibility of LENZ's innovative product in the medical community.
Read more →LENZLENZ Therapeutics Reports Second Quarter 2024 Financial Results
LENZ Therapeutics has reported its second quarter 2024 financial results, revealing significant advancements, including the submission of a New Drug Application (NDA) for LNZ100, aimed at treating presbyopia. The company announced positive results from its Phase 3 CLARITY study, demonstrating significant improvements in near vision. Additionally, LENZ secured its financial foundation through a $30 million private placement, enhancing its ability to support the upcoming commercial launch of LNZ100, pending regulatory approval.
Read more →LENZLENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia
LENZ Therapeutics announced the submission of a New Drug Application (NDA) for LNZ100 to the U.S. FDA for treating presbyopia. This submission follows positive results from the pivotal Phase 3 CLARITY study, which showed significant improvements in near vision without compromising distance vision. The FDA will review the NDA within a 60-day filing review period to determine its completeness and acceptability for further evaluation. If approved, LNZ100 aims to provide a pioneering treatment option for the 128 million individuals in the U.S. affected by presbyopia.
Read more →LENZLENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
LENZ Therapeutics, focused on developing an aceclidine-based eye drop for presbyopia, will report its second quarter 2024 financial results on August 14, 2024. The webcast will be accessible live and later via replay on the company's website. Their product candidate, LNZ100, has completed Phase 3 trials and aims to address the needs of a significant patient population affected by presbyopia worldwide.
Read more →LENZLENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
LENZ Therapeutics announced a $30 million investment from Ridgeback Capital aimed at bolstering the company's development of LNZ100, an aceclidine-based eye drop for presbyopia. This funding will support regulatory and pre-commercial activities leading to potential NDA submission mid-2024. LENZ's strong Phase 3 CLARITY study results underpin the optimism surrounding LNZ100 as a transformative treatment option for the millions affected by presbyopia.
Read more →LENZ▲ +14.2%on this news
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
LENZ Therapeutics has announced an upcoming Key Opinion Leader event scheduled for June 18, 2024, which will focus on the potential of LNZ100, an aceclidine-based eye drop for treating presbyopia. The event will feature presentations from esteemed experts and Principal Investigators involved in the Phase 3 CLARITY study, discussing real-world insights and current treatment landscapes. Attendees can participate through a live webcast, with materials available on the company's Investor Relations page.
Read more →LENZLENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
LENZ Therapeutics, a biopharmaceutical company specializing in treatments for presbyopia, announced that its CEO will present at the Jefferies Global Healthcare Conference on June 6, 2024. The company is developing LNZ100, an aceclidine-based eye drop designed to enhance near vision for people with presbyopia. The Phase 3 CLARITY study has been completed, setting a positive trajectory for its commercialization efforts. The conference will also feature one-on-one meetings with management to discuss the company's future plans.
Read more →LENZLENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
LENZ Therapeutics has reported encouraging financial and operational updates for the first quarter of 2024. The company announced positive topline results from its Phase 3 CLARITY study for presbyopia, indicating that LNZ100 is well-positioned for a New Drug Application submission in mid-2024. Additionally, LENZ has recently completed its merger with Graphite Bio, bolstering its financial position with approximately $213.3 million in cash. The anticipated commercial launch of LNZ100, if approved, could occur as early as the second half of 2025.
Read more →LENZLENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
LENZ Therapeutics announced that it will host a webcast on May 8, 2024, to report its first quarter financial results and provide a business update. The company specializes in developing aceclidine-based eye drops aimed at improving near vision for individuals with presbyopia. The product candidates have undergone evaluation in Phase 3 trials, emphasizing their commitment to addressing an important market need. The event will be accessible live and will be available for replay on their website.
Read more →LENZDocument LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials - LNZ100 selected as lead candidate - Primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-
LENZ Therapeutics announced positive topline data from its Phase 3 CLARITY trials for LNZ100, achieving significant efficacy in improving near vision for participants with presbyopia. The drug met the primary endpoint with 71% of participants achieving three-lines or greater improvement within three hours. LNZ100 was well-tolerated, with no serious adverse events reported, leading the company to plan for a New Drug Application submission in mid-2024. This promising data supports LNZ100's potential as a leading treatment option for the 128 million individuals affected by presbyopia in the United States.
Read more →LENZDocument Report of Independent Registered Public Accounting Firm To the Shareholders and the Board of Directors of Lenz Therapeutics, Inc. Opinion on the Financial Statements We have audited the accompanying balance shee
Lenz Therapeutics, Inc. has released its financial statements for the years ending December 31, 2022, and 2023. The audit indicates that the statements fairly present the company's financial position, but there is a dramatic increase in net loss and operational expenses over the reported period. Cash and cash equivalents have also diminished significantly, raising concerns about the company’s financial health. The report reflects ongoing challenges as the company navigates its financial performance.
Read more →LENZGraphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics Special dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger
Graphite Bio has declared a special dividend of $1.03 per share in conjunction with its proposed merger with Lenz Therapeutics. The payment will be made on March 21, 2024, but is contingent on the approval of the merger by Graphite's stockholders in a meeting scheduled for March 14, 2024. The total dividend payout is not expected to exceed $60 million, which will be determined after certain adjustments outlined in the merger agreement are made. The merger presents opportunities for the combined entity, given Lenz's focus on developing innovative eye therapies.
Read more →LENZLENZ Therapeutics and Graphite Bio Announce Merger Agreement - Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics lead assets for the treatment of presbyo
LENZ Therapeutics and Graphite Bio have announced a merger agreement to form a NASDAQ-listed biopharmaceutical company that will focus on advancing LENZ Therapeutics' lead assets for presbyopia treatment. The merger, which is subject to stockholder approval, will create a company with approximately $225 million in cash or cash equivalents, including funds from PIPE financing. The transaction is expected to close in the first quarter of 2024. The combined company aims to capitalize on a significant market opportunity in the U.S. exceeding $3 billion, addressing the vision needs of millions over 45 years of age.
Read more →LENZGraphite Bio Announces Departure of Chief Financial Officer
Graphite Bio, Inc. has announced the departure of Chief Financial Officer Alethia Young, who will leave to pursue other opportunities. She will remain with the company until June 30, 2023, to facilitate a smooth transition. The company's CEO expressed gratitude for Young's contributions since her joining last year, while Young expressed confidence in the finance and management team moving forward.
Read more →LENZGraphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results
Graphite Bio reported recent progress and its financial results for 2022, highlighting significant changes in its strategy. Notably, the company has decided to discontinue the development of its gene therapy candidate, nula-cel, following serious adverse events and has paused ongoing clinical trials. This decision resulted in a corporate restructuring aimed at preserving capital. The company, however, maintains a strong cash position while it explores strategic alternatives and continues research in other therapeutic areas.
Read more →LENZGraphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring
Graphite Bio has announced the discontinuation of its nula-cel program aimed at treating sickle cell disease following a review of its business and resources. The company plans to explore various strategic alternatives while also conducting a corporate restructuring, which will include a 50% reduction in workforce to minimize cash burn. Despite these challenges, Graphite Bio aims to continue research on its early-stage non-genotoxic conditioning program.
Read more →LENZGraphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease
Graphite Bio has announced a voluntary pause of its Phase 1/2 CEDAR study for nulabeglogene autogedtemcel (nula-cel) aimed at treating sickle cell disease, following a serious adverse event affecting the first patient dosed. The event resulted in prolonged low blood cell counts, prompting the company to reassess the treatment risks and strategy before continuing. The pause means that Graphite Bio will not meet its earlier plans for proof-of-concept data by mid-2023. The FDA has been informed of the situation, and the company is committed to the safety of its patients while evaluating next steps. Additionally, the delay impacts timelines for future applications related to other conditions, such as beta-thalassemia.
Read more →LENZGraphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64 th ASH Annual Meeting Single-cell RNA sequencing of reticulocytes will be used to measure gene correction o
Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting Single-cell RNA sequencing of reticulocytes will be used to measure gene correction outcomes in sickle cell patients treated with nulabeglogene a
Read more →LENZGraphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results Dosed first sickle cell patient with nula-cel; initial proof-of-concept data on track for mid-2023 Two abstracts accepted for 64 th A
Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results Dosed first sickle cell patient with nula-cel; initial proof-of-concept data on track for mid-2023 Two abstracts accepted for 64th ASH Annual Meeting and Exposition in December Entered strat
Read more →LENZGraphite Bio Announces Abstracts Accepted for Upcoming 64 th ASH Annual Meeting and Exposition
Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition SOUTH SAN FRANCISCO, Calif., November 3, 2022 Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision
Read more →LENZGraphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease GPH101, now called nulabeglogene autogedtemcel (nula-cel), designed to directly correct the genetic mutation that
Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease GPH101, now called nulabeglogene autogedtemcel (nula-cel), designed to directly correct the genetic mutation that causes sickle cell disease Initial proof-of-concept data f
Read more →LENZGraphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results Dosed first patient with nulabeglogene autogedtemcel (nula-cel), formerly known as GPH101, in Phase 1/2 CEDAR clinical trial in peop
Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results Dosed first patient with nulabeglogene autogedtemcel (nula-cel), formerly known as GPH101, in Phase 1/2 CEDAR clinical trial in people with sickle cell disease; initial proof-of-concept data
Read more →LENZGraphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting Trial-in-progress poster of Phase 1/2 CEDAR trial evaluating GPH101 for sickle cell disease to be p
Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT Trial-in-progress poster of Phase 1/2 CEDAR trial evaluating GPH101 for sickle cell disease to be presented as an encore SOUTH SAN FRANCISCO, Calif., May 16, 2022 Graphite Bio,
Read more →LENZGraphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results GPH101 for sickle cell disease granted U.S. FDA Fast Track Designation; dosing of first patient in Phase 1/2 CEDAR clinical trial on
Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results GPH101 for sickle cell disease granted U.S. FDA Fast Track Designation; dosing of first patient in Phase 1/2 CEDAR clinical trial on track for second half of 2022, with initial proof-of-concep
Read more →LENZGraphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2021 Financial Results Patient enrollment in Phase 1/2 CEDAR clinical trial of GPH101 for sickle cell disease ongoing at multiple sites; do
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2021 Financial Results Patient enrollment in Phase 1/2 CEDAR clinical trial of GPH101 for sickle cell disease ongoing at multiple sites; dosing of first patient now planned for second half of 2022,
Read more →LENZLearn more about Graphite Bio by visiting www.graphitebio.com and following the company on LinkedIn . ### Company Contact: Stephanie Yao VP, Communications and Investor Relations 443-739-1423 syao@graphitebio.com Investo
Graphite Bio Appoints Alethia Young as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., March 2, 2022 - Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure seri
Read more →LENZGraphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease GPH101 designed to directly correct the genetic mutation responsible for sickle cell disease First patient expected to be t
Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease GPH101 designed to directly correct the genetic mutation responsible for sickle cell disease First patient expected to be treated in first half of 2022, with initial proof-of-concep
Read more →LENZGraphite Bio Reports Recent Business Progress and Third Quarter 2021 Financial Results Recruitment for Phase 1/2 CEDAR clinical trial of GPH101 for sickle cell disease underway at multiple sites Details about CEDAR trial
Graphite Bio Reports Recent Business Progress and Third Quarter 2021 Financial Results Recruitment for Phase 1/2 CEDAR clinical trial of GPH101 for sickle cell disease underway at multiple sites Details about CEDAR trial to be presented at 63rd ASH Annual Meeting and Exposition
Read more →LENZGraphite Bio Reports Recent Business Progress and Second Quarter 2021 Financial Results On track to enroll first patient in Phase 1/2 clinical trial of GPH101 for sickle cell disease in the second half of 2021 Expanded l
Graphite Bio Reports Recent Business Progress and Second Quarter 2021 Financial Results On track to enroll first patient in Phase 1/2 clinical trial of GPH101 for sickle cell disease in the second half of 2021 Expanded leadership team with hiring of CSO and three new appointmen
Read more →Competitive Position
How LENZ ranks across every disease it competes inCompetitive Position is a premium feature
See how LENZ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial